Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 11Breast 11Other hematologic neoplasm 5Thoracic 4Plasma cell 2Other solid neoplasm 2Other 2Myeloid 2Gynecologic 2Genitourinary 2Dermatologic 2Sarcoma 1CNS 1

Conditions

Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Cardiotoxicity 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Echocardiography × Dermatologic × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT06605833 2025-10-01

CARD-IO

Royal Marsden NHS Foundation Trust

Enrolling by invitation
60 enrolled
Dermatologic

Melanoma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡